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Macrophage (Mf) activation, as measured by cell surface expression of MHC class II, was examined during infection of
immunocompetent and immunocompromised mice with murine cytomegalovirus (MCMV). Intraperitoneal infection of CB17
SCID mice with 106 PFU of MCMV elicited a large population of Mf which expressed low levels of MHC class II. This was
surprising since infection of SCID mice with lower doses (e.g., 104 PFU) of MCMV elicits Mf expressing high levels of MHC
class II (M. T. Heise and H. W. Virgin, J. Virol. (1995) 69, 904–909). In vivo administration of recombinant mouse IFNg resulted
in high levels of MHC class II expression on Mf from control but not MCMV-infected SCID mice, suggesting that MCMV
infection generates a state in which IFNg is not effective at activating Mf. The effect of MCMV infection was MHC class II
specific, since MHC class I and ICAM-1 levels were increased on Mf expressing low levels of MHC class II. Interference
with IFNg action was not due to productive or abortive infection of Mf. This suggested that MCMV infection induces a
soluble factor that alters Mf responsiveness to IFNg. Infection of SCID mice with 106 PFU of MCMV induced higher levels
of serum IFNab (one candidate for inhibition of IFNg induction of MHC class II expression) than infection with 104 PFU. We
therefore evaluated the role of MCMV-induced IFNab on IFNg responses of bone marrow-derived (BMMf) or thioglycollate-
elicited Mf in vitro. Infection of normal Mf with MCMV at a low m.o.i. (0.1 to 0.2) impaired IFNg-mediated induction of Mf
MHC class II expression, but not MHC class I expression. Inhibition of IFNg responses was not observed in Mf from mice
with a null mutation in the IFNab receptor (IFNabR2/2). To test the in vivo relevance of virus-induced IFNab to
IFNg-mediated responses, the kinetics of MHC class II induction during MCMV infection of IFNabR2/2 mice was evaluated.
MCMV-infected IFNabR2/2 mice mounted an earlier Mf MHC class II response than normal mice. We conclude that MCMV
infection specifically impairs IFNg-mediated MHC class II expression on Mf and that induction of IFNab is one mechanism
by which this inhibition occurs. © 1998 Academic Press
INTRODUCTION
HCMV is an important pathogen in immunocompro-
mised individuals, such as those with acquired immune
deficiency syndrome, bone marrow transplant recipients,
and recipients of solid organ transplants (Britt and Alford,
1996). Infection with murine cytomegalovirus (MCMV)
serves as a useful model for analysis of host responses
to CMV. Both innate (T and B cell independent) and
specific immunity play a role in control of CMV infection.
Specific immunity is mediated largely by T lymphocytes,
with CD8 T cells being primarily responsible for viral
clearance of peripheral organs (Jonjic et al., 1990; Red-
dehase et al., 1987). CD4 T cells are required for clear-
ance of the salivary glands (Jonjic et al., 1989) through an
IFNg-dependent mechanism (Lucin et al., 1992). Innate
responses also play a crucial role in resistance to
MCMV. NK cells, which are capable of acting indepen-
dently of T and B lymphocytes, are important in MCMV
resistance (Bancroft et al., 1981; Bukowski et al., 1984;
Shanley, 1990; Welsh et al., 1991). Studies using neutral-
izing antibodies or exogenous cytokine administration
have also demonstrated a role for IFNg, TNFa, IL12, and
IFNab in resistance to MCMV (Chong et al., 1983;
Cousens et al., 1997; Fennie et al., 1988; Heise and
Virgin, 1995; Lucin et al., 1992; Orange and Biron, 1996;
Orange et al., 1995; Pavic et al., 1993). IFNg secreted by
NK cells is likely a major mediator of innate resistance to
MCMV (Heise and Virgin, 1995; Orange et al., 1995). Of
particular note is the role of IFNg in multiple situations
including acute infection of immunocompromised and
immunocompetent mice, as well as in clearance of per-
sistent infection of the salivary gland.
Macrophages (Mf) also play an important role in CMV
pathogenesis. Mf are, under certain activation/differen-
tiation conditions, permissive for HCMV or MCMV infec-
tion (Brautigam et al., 1979; Fish et al., 1995; Heise and
Virgin, 1995; Ibanez et al., 1991; Lathey and Spector, 1991;
Maciejewski et al., 1993; Shanley and Pesanti, 1983). Mf
activation occurs in vivo during MCMV infection. For
example, ip infection of normal or immunocompromised
SCID mice [lacking functional B and T cells (Custer et al.,
1985)] with MCMV induces an inflammatory infiltrate
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consisting largely of Mf (Heise and Virgin, 1995). These
Mf are activated as shown by increased expression of
Fc receptors (Price et al., 1987), as well as MHC class II,
MHC class I, and ICAM-1 (Heise and Virgin, 1995). One
of the primary mediators of Mf activation during MCMV
infection is IFNg (Heise and Virgin, 1995). Mononuclear
phagocytes (likely Mf) are also involved in the dissem-
ination of HCMV and MCMV during primary infection
(Collins et al., 1994; Saltzman et al., 1988; Stoddart et al.,
1994). Mf or Mf precursors also play a role in HCMV
latency (Kondo et al., 1994; Maciejewski et al., 1992;
Minton et al., 1994; Pollock et al., 1997; Rice et al., 1984;
Taylor-Wiedeman et al., 1991, 1994). Given the critical role
of Mf in multiple stages of CMV pathogenesis, we rea-
soned that defining the regulation of Mf activation/dif-
ferentiation during MCMV infection is critical to under-
standing acute and chronic CMV infection. Of particular
interest would be mechanisms by which MCMV inhibits
Mf activation by IFNg.
Viruses have been shown to impair the host immune
response via a number of mechanisms. These include: (i)
destruction of cells essential for normal immune function
such as occurs with CD4 T cells during HIV infection, (ii)
expression of viral glycoproteins homologous to host
cytokines or cytokine receptors which interfere with or
skew the anti-viral inflammatory response, and (iii) inhi-
bition of antigen presentation to CD4 or CD8 T cells. Of
interest to this study, viral infection has previously been
shown to impair Mf function. For example, LCMV and
HCMV impair Mf function via induction of IFNab in vitro
(Scholz et al., 1992; Sedmak et al., 1995; Villarete et al.,
1995). In addition, studies of both MCMV and LCMV
show that IFNab can regulate IL-12 and IFNg responses,
suggesting that IFNab might regulate macrophage acti-
vation during MCMV infection (Cousens et al., 1997). We
investigated the effects of MCMV infection on Mf acti-
vation and demonstrated a role for MCMV induced
IFNab in impairing IFNg-induced MHC class II expres-
sion on Mf both in vivo and in vitro.
RESULTS
Low-level Mf MHC class II expression after
high-dose MCMV infection
Infection of immunodeficient CB17 SCID mice with
103–4 PFU of MCMV or 106 PFU of HSV strain KOS results
in a peritoneal exudate containing Mf with increased
cell surface expression of MHC class II, MHC class I,
and ICAM-1, as well as decreased F4/80 expression
(Heise and Virgin, 1995). F4/80 is a macrophage-specific
cell surface marker (Austyn and Gordon, 1981; Starkey et
al., 1987). These results demonstrate that infection with
low doses of MCMV induces Mf MHC class II expres-
sion in the absence of a contribution of the specific
immune response. To examine the ability of the innate
immune system to respond to more severe MCMV infec-
tion, we infected CB17 SCID mice with 106 PFU of MCMV.
In contrast to infection with lower doses (e.g., 104 PFU,
Fig. 1), peritoneal Mf harvested 7 days after infection
with 106 PFU of MCMV expressed only low levels of
MHC class II (Fig. 1). Based on the ability of 104 PFU of
MCMV to induce high-level MHC class II expression on
peritoneal Mf, it was surprising that infection with a
higher dose of MCMV did not induce increased MHC
class II expression. We therefore evaluated the apparent
difference in the percentage of Mf expressing high
levels of MHC class II following infection with either low
doses (104 PFU) or high doses (106 PFU) of MCMV. Total
cell yield, the percentage of Mf in the total exudate, and
the percentage of Mf which were MHC class II high
were evaluated following MCMV infection. Infection with
higher doses of MCMV (105–6 PFU) induced a large
infiltrate of MHC class II low Mf, which was not ob-
served during infection with lower doses (103–4 PFU)(Fig.
2). No significant difference was observed in the overall
number of MHC class II high Mf at any dose of MCMV.
Therefore, the observed decrease in the percentage of
MHC class II high Mf following infection with high
doses of MCMV was due to dilution of the MHC class II
high Mf by the influx of MHC class II low cells.
MCMV infection actively inhibits IFNg-induced MHC
class II expression on peritoneal Mf
It was possible that insufficient IFNg was produced dur-
ing the innate response to severe MCMV infection to in-
duce high-level MHC class II expression. This was a strong
possibility since previous work showed that IFNab induc-
tion during MCMV infection can decrease IL-12 and IFNg
levels and this might lead to a failure to activate Mf
(Cousens et al., 1997; Orange and Biron, 1996). Alternatively,
MCMV infection might impair Mf responsiveness to IFNg
during the innate phase of the immune response. To dis-
tinguish between these possibilities, recombinant mouse
IFNg was administered to SCID mice that were mock in-
fected or infected with 106 PFU of either MCMV, HSV strain
KOS, or UV-inactivated MCMV. If insufficient IFNg was
present during MCMV infection of SCID mice to induce
MHC class II expression on the entire Mf population,
exogenous IFNg should overcome the lack of high levels of
MHC class II expression. Exogenous IFNg induced high
levels of MHC class II expression on the majority of peri-
toneal Mf from SCID mice which were either mock in-
fected or challenged with HSV or UV-inactivated MCMV
(Fig. 3). In contrast, while exogenous IFNg did increase the
level of MHC class II expression on Mf from SCID mice
infected with MCMV, the majority of Mf remained MHC
class II low. By immunofluorescent microscopy, Mf from
mock, HSV, or UV-inactivated MCMV infected SCID mice
were 55–80% MHC class II positive, while only 6% of Mf
from MCMV-infected SCID mice treated with IFNg were
MHC class II positive. The overall Mf yield was not signif-
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icantly different between the IFNg-treated groups with or
without MCMV infection (data not shown). Thus infection
with high doses of MCMV impairs Mf responsiveness to
IFNg. This effect is independent of effects of MCMV infec-
tion on production of IL-12 and IFNg (Cousens et al., 1997).
Inhibition of Mf surface protein expression is
specific for MHC class II
To test whether the lack of high levels of MHC class II
expression on Mf following infection with 106 PFU of
MCMV was part of a general defect in Mf surface protein
expression, we evaluated expression of MHC class I and
ICAM-1 (Fig. 4). In contrast to MHC class II expression,
levels of both MHC class I and ICAM-1 were increased or
unchanged on Mf following infection with 106 PFU of
MCMV (Fig. 4), demonstrating that the low level of Mf MHC
class II expression following MCMV infection was not part
of a general defect in Mf cell surface protein expression.
Lack of Mf MHC class II expression is not due to
infection of Mf in vivo
MCMV might impair Mf MHC class II expression via
a number of different mechanisms. A likely possibility
was direct inhibition of MHC class II expression in in-
FIG. 1. Increasing doses of MCMV result in decreased MHC class II expression on Mf. CB17 SCID mice were mock infected or infected with 104 or 106
PFU of MCMV. Seven days postinfection, PECs were harvested and Mf MHC class II (IEd) and F4/80 expression was determined by flow cytometry. (A)
Two-color histograms for whole PEC population. (B) Single-color histograms (MHC class II, IEd) gated specifically on the Mf population from A. The dotted
line in single-color histograms represents unstained cells and the solid line represents MHC class II staining. Results are shown from one representative
experiment. Experiments were performed with comparable results as follows: Mock, 5 times; 104 PFU of MCMV, 4 times; 106 PFU of MCMV, 6 times.
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fected cells similar to the inhibition of MHC class I
expression seen in fibroblasts infected in vitro by MCMV
or HCMV (Beersma et al., 1993; Campbell and Slater,
1994; Del Val et al., 1992; Gilbert et al., 1993; Jones et al.,
1995). To assess whether Mf were productively infected,
PECs from SCID mice infected with 106 PFU of MCMV
were harvested on day 7 postinfection, and the fre-
quency of productively infected cells determined by lim-
iting dilution analysis (Taswell, 1981). Over five experi-
ments the frequency of productively infected PECs varied
from 1:165 to 1:1615 (Table 1). Since 80 to 85% of perito-
neal cells from MCMV-infected SCID mice are Mf
(Heise and Virgin, 1995), and assuming that all of the
productively infected PECs are Mf, the maximum per-
centage of Mf productively infected is 0.75%. Since 85 to
90% of peritoneal Mf from mice infected with 106 PFU of
MCMV are MHC class II low, productive infection did not
explain low-level expression of Mf MHC class II.
Though productive infection did not explain MCMV’s
inhibition of Mf MHC class II expression, MCMV might
abortively infect Mf, resulting in inhibition of IFNg re-
sponsiveness. To address this possibility we evaluated
peritoneal Mf for carriage of MCMV genome using a
limiting dilution PCR assay. PECs from SCID mice in-
fected with 106 PFU of MCMV were serially diluted and
assessed for MCMV genome by PCR (Fig. 5). In control
experiments 1 copy of plasmid DNA carrying the ie1
sequence was detected 15/35 times when added to 103
peritoneal exudate cells, while 5 copies were detected
9/10 times and 10 copies 32/36 times. Since we consis-
tently detected 5 to 10 copies of target plasmid, we
assumed that a negative PCR reaction indicated that
fewer than 10 copies of MCMV genome were present.
We found that, similar to the limiting dilution results for
productive infection (Table 1), there was a 10-fold varia-
tion between experiments in the number of samples
positive for MCMV genome (Table 2). However, MHC
class II expression was low (Fig. 5B) when 87% (exper-
iment 1) to 93% (experiment 4) of samples containing 100
PECs contained fewer than 10 copies of the MCMV
genome. Even in experiment 2, samples containing 10
PECs were positive only 12.5% of the time. Since Mf
comprise 80 to 85% of the peritoneal infiltrate, and even
assuming that an abortively infected cell contains only a
single copy of the MCMV genome, the frequency of
MCMV genome-positive cells is insufficient for abortive
infection of the Mf to explain the low level of MHC class
II expression on 90% of peritoneal Mf.
IFNab induction as a candidate for inhibition of Mf
activation in vivo
The above data are consistent with MCMV infection
inhibiting Mf responsiveness to IFNg by a mechanism
independent of productive or abortive MCMV infection of
Mf. We therefore considered the possibility that MCMV
infection induced a host cytokine which inhibits Mf
responses to IFNg. One candidate cytokine was IFNab,
which has been shown to directly impair IFNg-mediated
MHC class II expression (Inaba et al., 1986). We there-
fore examined IFNab levels in SCID mice infected with
either 104 or 106 PFU of MCMV. We found that 106 PFU of
MCMV induced significantly more serum IFNab than low
doses of MCMV (Fig. 6). The IFNab levels we observed
48 h after infection of SCID mice were consistent with
previous reports of IFNab induction after MCMV infec-
tion of immunocompetent mice (Grundy et al., 1982;
Kelsey et al., 1977; Orange and Biron, 1996; Tarr et al.,
1978). Interestingly, previous studies documented that
IFNab levels decrease in immunocompetent mice by 7
days of infection (Allan and Shellam, 1985; Kelsey et al.,
1977; Tarr et al., 1978), whereas we found that IFNab
levels were still high in SCID mice 7 days after infection
with 106 PFU of MCMV (Fig. 6). We confirmed that immu-
nocompetent mice have no detectable IFNab in serum 7
days after infection with either 104 or 106 PFU of MCMV
(sensitivity 14 U/ml, not shown). The continued presence
of IFNab in vivo in immunocompromised SCID mice
could inhibit IFNg-induced Mf MHC class II.
MCMV infection directly impairs IFNg-induced MHC
class II expression in Mf cultures in vitro
To more definitively address the hypothesis that
IFNab induced by MCMV can alter Mf responsiveness
FIG. 2. The decreased percentage of MHC class II-positive Mf
following infection with 106 PFU of MCMV is due to an influx of Mf
expressing low levels of MHC class II. SCID mice were infected ip with
103–6 PFU of MCMV. PECs were harvested on day 7 postinfection and
counted to determine cell yield per mouse. Differential counts were
performed in a blinded manner to determine the total number of Mf per
mouse in the inflammatory infiltrate. The percentage of class II-positive
Mf was determined by flow cytometry. The total numbers of MHC
class II-positive and -negative Mf per group were determined by
multiplying the percentage of MHC class II-positive Mf by the total
number of Mf per mouse. The bars represent the number of MHC
class II high or low Mf per mouse 6 SEM. Experiments were per-
formed as follows: Mock, 5 times; 103 PFU of MCMV, 2 times; 104 PFU
of MCMV, 4 times; 105 PFU, twice; 106 PFU, 6 times.
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to IFNg we turned to in vitro analysis of the effects of
MCMV infection on Mf IFNg responsiveness. We eval-
uated MHC class II expression on BMMf or thioglycol-
late elicited PECs infected with MCMV. Mf were mock
infected or infected with UV-inactivated MCMV or MCMV
for 24 h at a m.o.i. of 0.2 (BMMf) or 0.25 (PECs). Twenty-
four hours after MCMV infection, the cultures were
treated with 500 U/ml of recombinant mouse IFNg for
48 h. This dose of IFNg is about fivefold higher than the
dose needed to generate maximal MHC class II induc-
tion in uninfected BMMf (data not shown). Mf were
harvested and counted, and viability was determined by
trypan blue exclusion. Cells from mock-infected or
MCMV-infected cultures were 98 to 100% viable. The cell
yield was generally twofold lower for MCMV and UV-
inactivated MCMV-infected cultures compared to mock-
infected cultures. MHC class II and MHC class I levels
were determined by flow cytometry. Mock-infected Mf
responded to IFNg, with significant induction of both
MHC class I and II expression (Fig. 7). However, infection
with live MCMV resulted in a significant decrease in
MHC class II expression compared to both mock-in-
fected and UV-inactivated MCMV groups. Similar to the
results obtained in vivo (Fig. 4), even though IFNg-medi-
ated induction of MHC class II levels was inhibited, MHC
class I levels were identical or higher in the MCMV-
infected BMMf cultures compared to mock-infected
controls. Given the ability of both MCMV and HCMV to
inhibit MHC class I expression in infected cells
(Beersma et al., 1993; Campbell and Slater, 1994; Del Val
et al., 1992; Gilbert et al., 1993; Jones et al., 1995), these
results suggest that the majority of Mf in these cultures
were not infected. In contrast to the in vivo results (Fig.
3), infection with UV-inactivated MCMV did decrease
MHC class II expression in vitro, though to a smaller
degree than live MCMV.
Role of IFNab in MCMV inhibition of Mf MHC class
II expression in vitro
To test the hypothesis that IFNab released from in-
fected cells in vitro was responsible for inhibition of IFNg
responses, BMMf from wildtype 129 or IFNabR2/2
mice were infected with MCMV at a low m.o.i. and
IFNg-mediated MHC class II induction was measured.
Unlike wildtype Mf, MCMV infection of IFNabR2/2
BMMf cultures did not result in decreased cell yields
compared to uninfected cultures (data not shown). This
FIG. 3. Exogenous IFNg is unable to overcome the lack of high-level MHC class II expression on Mf from SCID mice infected with 106 PFU of
MCMV. (A) Control; (B) experimental. SCID mice were mock infected or infected with 106 PFU of MCMV, HSV KOS, or UV-inactivated MCMV.
Exogenous murine IFNg (3 mg/mouse) was administered ip on days 4–6 postinfection. PECs were harvested on day 7 postinfection and MHC class
II expression was determined by flow cytometry. Top panels are mock infected with and without exogenous IFNg. Bottom panels are MCMV, HSV,
or UV MCMV-infected groups treated with exogenous mouse IFNg. Shown are two of three comparable experiments.
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suggests that the decrease in cell yield observed upon
MCMV infection of wildtype Mf cultures is due to IFNab.
While MCMV infection of 129 BMMf led to specific
reduction of IFNg-induced MHC class II expression, in-
fection of IFNabR2/2 BMMf with MCMV did not re-
duce IFNg-induced MHC class II expression (Fig. 8A). To
confirm that BMMf from IFNabR2/2 mice did not re-
spond to IFNab, control 129 or IFNabR2/2 BMMf were
incubated with 500 units of murine IFNab for 48 h and
analyzed for MHC class I expression. IFNa/b treatment
resulted in increased MHC class I expression by wild-
type 129, but not IFNabR2/2 BMMf (Fig. 8B). Adminis-
tration of neutralizing polyclonal antibody against IFNab
also blocked MCMV-mediated inhibition of IFNg-induced
MHC class II expression in wildtype Mf cultures (data
not shown). Furthermore, supernatants from MCMV-in-
fected Mf cultures, from which free virus had been
removed by ultracentrifugation, impaired IFNg-induced
MHC class II expression on naive cultures of wildtype
129, but not IFNabR2/2 BMMf (data not shown).
Effects of MCMV-induced IFNab on Mf MHC class II
expression in immunocompetent mice
Since virally induced IFNab played a role in the inhi-
bition of IFNg-mediated MHC class II induction during
MCMV infection in vitro (Fig. 8), we evaluated the poten-
tial role of MCMV-induced IFNab in impaired Mf MHC
class II expression during the innate phase of the im-
mune response in vivo. MHC class II expression on
peritoneal Mf was examined over time following infec-
tion of immunocompetent CB17 or 129 mice with 106 PFU
of MCMV (Fig. 9A). We have previously demonstrated
that MCMV infection induces high-level Mf MHC class II
expression in immunocompetent CB17 mice by day 7
postinfection (Heise and Virgin, 1995). In agreement with
this work, infection with 106 PFU of MCMV did induce
high-level MHC class II expression on Mf at day 7
postinfection. However, at early time points (day 3), high-
level Mf MHC class II expression was not observed.
Based on these results, we reasoned that if MCMV-
induced IFNab decreased Mf responsiveness to IFNg,
IFNabR2/2 mice should have enhanced MHC class II
expression at early times post MCMV infection.
IFNabR2/2 mice or wildtype controls were infected
with 106 PFU of MCMV. PECs were harvested on day 3
postinfection and MHC class II expression determined
by flow cytometry (Fig. 9B). MCMV infection of
IFNabR2/2 mice resulted in increased MHC class II
expression on peritoneal Mf compared to wildtype con-
trols on day 3 postinfection (Figs. 9B and 9C).
IFNabR2/2 mice had splenic MCMV titers which were
over 2 logs higher than those of wildtype mice
(IFNabR2/2 5 5.3 6 0.1 log, wildtype 129 5 2.9 6 0.2
log, n 5 3). Therefore, an alternative explanation for the
more rapid induction of MHC class II expression in
IFNabR2/2 mice was that higher viral loads in these
animals were responsible for greater stimulation of IFNg
production, rather than a direct effect of IFNab on Mf
MHC class II expression. To address this issue, wildtype
129 mice were infected with 108 PFU of MCMV, which
resulted in splenic titers of 5.0 6 0.5 log on day 3
postinfection. In spite of the higher challenge dose, MHC
class II expression was still low on the wildtype 129
TABLE 1
Frequency of PECs Productively Infected with MCMV
in Acutely Infected SCID Mice
Experiment Frequency of infected cells Reciprocal of frequency
1a 6.18 3 1024 6 6.9 3 1025 1/1615
2a 6.05 3 1023 6 5.9 3 1024 1/165
3a 7.98 3 1024 6 5.7 3 1025 1/1253
4b 3.67 3 1023 6 4.2 3 1024 1/272
5b 1.34 3 1023 6 1.2 3 1024 1/746
a Two week culture read every 7 days.
b Four week culture read every 7 days.
FIG. 4. MHC class I and ICAM-1 levels are unchanged or increased
on the MHC class II low Mf from SCID mice infected with 106 PFU of
MCMV. SCID mice were infected with 106 PFU of MCMV or mock
infected. PECs were harvested on day 7 postinfection and MHC class
I (H-2Kd)(A) and ICAM-1 (B) levels determined by flow cytometry with
gates set on the Mf population. Results shown are from one repre-
sentative experiment. Experiments were performed a total of six times.
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peritoneal Mf on day 3 postinfection (not shown), sug-
gesting that the increased MHC class II expression in
IFNabR2/2 mice is independent of viral load. These
data are consistent with a role for virally induced IFNab
in modifying IFNg-mediated events during the course of
MCMV infection in vivo.
DISCUSSION
We have analyzed Mf activation during the innate
immune response to severe MCMV infection. SCID mice,
which served as a model system for study of the innate
immune response due to their lack of a specific immune
system, did not exhibit high-level Mf MHC class II ex-
pression following challenge with 106 PFU of MCMV,
while infection with lower doses of MCMV did induce
high-level MHC class II expression. Using SCID mice,
we demonstrate that the lack of high-level Mf MHC
class II expression during high-dose MCMV infection: (1)
is specific for MHC class II and not due to a generalized
defect in Mf surface protein expression, (2) is associ-
ated with poor Mf responsiveness to IFNg, (3) requires
live virus, and (4) is not due to productive or abortive
infection of Mf by MCMV in vivo. Furthermore, we dem-
onstrate a role for MCMV-induced IFNab in impairing
IFNg-induced Mf MHC class II expression both in vitro
and in vivo. Given the importance of Mf in regulation of
the immune response (Unanue and Allen, 1987), the
interplay of the two interferon systems may have impor-
tant consequences in the generation of an effective im-
mune response during MCMV infection (Cousens et al.,
1997). In particular, continued expression of IFNab dur-
ing severe infection may blunt the adaptive immune
response, resulting in failure to mount effective immunity.
Inflammatory Mf can be highly responsive to IFNg
stimulation, as measured by increased MHC class II
expression (Beller and Ho, 1982). Therefore it was sur-
prising to observe that high-level MHC class II expres-
sion was not present on the majority of Mf from immu-
nodeficient CB17 SCID mice infected with 106 PFU of
MCMV (Fig. 1). MCMV could inhibit IFNg-mediated MHC
class II induction by a number of different mechanisms,
including direct infection of the Mf or production of a
soluble inhibitory mediator of viral or host origin. Direct
infection of the Mf was a likely candidate, since Mf are
permissive for MCMV infection (Introduction), and Mf-
like cells in the peripheral blood carry MCMV during
acute infection (Collins et al., 1994; Stoddart et al., 1994).
Using a highly sensitive coculture assay (Table 1) and a
limiting dilution PCR method (Fig. 5, Table 2), we were
able to demonstrate that MCMV’s effects on Mf MHC
class II expression were not due to direct infection of the
Mf. This raised the possibility that MCMV affected Mf
MHC class II expression in an indirect manner, perhaps
via inhibition of production of critical cytokines or induc-
tion of a soluble mediator that inhibited IFNg responses.
It was possible that NK cells responding during the
TABLE 2
Detection of MCMV Genome by Nested PCR of Limiting Dilutions
of PECs from MCMV Infected SCID Mice
Experiment
Positive reactions/total reactions (cells/reaction)
1000 100 10
1 29/36 (80%) 4/30 (13%) N.D.
2 22/23 (96%) 24/24 (100%) 3/24 (12.5%)
3 33/36 (92%) 15/36 (42%) 8/24 (33%)
4 16/24 (67%) 1/16 (6%) 0/12
Note. N.D., not done.
FIG. 5. SCID PECs carry insufficient MCMV genome for abortive
infection to explain the lack of high-level MHC class II expression.
SCID mice were infected with 106 PFU of MCMV. Seven days postin-
fection, PECs were harvested and aliquotted at 1000, 100, or 10 cells/
tube, with 12 to 36 tubes per dilution. (A) Cells were lysed and lysate
was subjected to nested PCR for the MCMV ie1 gene. Lanes 1–12,
SCID PEC lysate; lane 13, 1-kb marker; lane 14, quality control (H2O
alone) for tube cross-contamination. Control group: Lanes 1 to 4,
mock-infected cell lysate; lanes 5 to 8, Mock lysate 1 one copy MCMV
ie1; lanes 9 to 12, Mock lysate 1 10 copies MCMV ie1. (B) MHC class
II (IAd) and F4/80 expression on PECs used for PCR analysis was
confirmed by flow cytometry.
337MCMV INHIBITION OF Mf MHC CLASS II EXPRESSION
innate phase of the immune response to MCMV were
unable to express enough IFNg to induce high-level
MHC class II expression on the large number of inflam-
matory Mf present during infection with 106 PFU of
MCMV (Fig. 2). We knew that IFNg was produced at
some level in SCID mice infected with 106 PFU of MCMV,
since neutralization of IFNg results in increased viral titer
in the spleen and liver compared to mice receiving virus
alone (Heise and Virgin, 1995). This suggested that,
rather than an inability of SCID mice to produce sufficient
IFNg, the observed defect in Mf MHC class II expres-
sion might be due to an effect of MCMV infection on Mf
IFNg responsiveness. This was confirmed by the poor
response of Mf from MCMV-infected SCID mice to ex-
ogenously administered IFNg (Fig. 3). This adds direct
inhibition of Mf IFNg responsiveness to already demon-
strated inhibition of IL-12 and IFNg expression (Cousens
et al., 1997) as mechanisms by which IFNab alters im-
mune responses during viral infection.
We found that IFNab production was one mechanism
by which MCMV infection could alter Mf responsive-
ness to IFNg. Both a interferons and b interferon have
been shown to inhibit IFNg-mediated MHC class II in-
duction in vitro (Inaba et al., 1986). IFNb has also been
demonstrated to play a role in HCMV-mediated inhibition
of MHC class II expression on endothelial cells (Sedmak
et al., 1995). Consistent with this in vitro work, we have
demonstrated that mice lacking a functional IFNab re-
ceptor do not exhibit the delay in Mf MHC class II
expression observed in wildtype mice (Fig. 9). This sug-
gests that during the early stages of acute MCMV infec-
tion, IFNab production results in a delay in IFNg-medi-
ated MHC class II expression. This is likely due to a
FIG. 6. IFNab levels in serum after infection of SCID mice with
MCMV. Groups of three to five CB17 SCID mice were infected with the
indicated dose of MCMV and sacrificed 8, 24, 48, or 168 h after
infection. Serum was collected and assayed for IFNab activity as
described under Materials and Methods. Results from this experiment
are consistent with those obtained in three similar experiments. Data
are presented as the mean serum IFNab concentration 6 SEM.
FIG. 7. MCMV infection inhibits IFNg-induced MHC class II, but not MHC class I, expression on cultured Mf. BMMf- or thioglycollate-elicited
peritoneal Mf were mock infected or infected with MCMV or UV-inactivated MCMV at an m.o.i. of 0.2 (BMMf) or 0.25 (peritoneal Mf). At 24 h
postinfection recombinant mouse IFNg (500 U/ml) or medium alone was added to the cultures. At 48 h after the addition of IFNg, cells were harvested
and MHC class II (IEd) and MHC class I expression was determined by flow cytometry. Results shown are one representative experiment using bone
marrow Mf and thioglycollate-elicited Mf. Experiments were performed a total of four times for BMMf and three times with thioglycollate-elicited
peritoneal Mf.
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combination of IFNab effects on induction of IL-12, in-
duction of IFNg, and direct inhibition of Mf responsive-
ness to IFNg [(Cousens et al., 1997) and this paper]. The
high-level MHC class II expression observed in immu-
nocompetent mice on day 7 postinfection with high
doses of MCMV (Heise and Virgin, 1995) indicates that
the effects of IFNa/b are eventually overcome. This likely
reflects decreased production of IFNab [(Allan and Shel-
lam, 1985; Kelsey et al., 1977; Tarr et al., 1978) and data
not shown], increased IFNg production as immune cells
are recruited, and possibly production of a second me-
diator capable of acting synergistically with IFNg to in-
duce MHC class II expression. Though MCMV’s effects
on Mf MHC class II expression are observed only dur-
ing the innate phase of the host immune response, this
could impact the specific host response to MCMV. Inhi-
bition of antigen presentation via MHC class II would
impair CD4 T-cell-mediated responses to MCMV and
possibly skew the host response toward CD8 T cells
which are important for the control of MCMV infection in
organs such as spleen (Jonjic et al., 1990; Reddehase et
al., 1987).
In addition to its effects on Mf responsiveness to
IFNg, IFNab is also an inhibitor of lymphocyte prolifera-
tion (Lindahl-Magnusson et al., 1972). Interestingly, acute
MCMV infection has been reported to cause defects in
lymphocyte proliferation (Loh and Hudson, 1982) and
antibody production (Bixler and Booss, 1981; Osborn et
al., 1968), as well as increasing susceptibility to infection
with other pathogens (Hamilton and Overall, 1978; Ham-
ilton et al., 1976). The immunosuppressive effects of
MCMV have been suggested to involve viral infection of
adherent spleen cells or monocytes, leading to produc-
tion of a suppressive factor (Bixler and Booss, 1981;
Kapasi and Rice, 1986). Lymphocytic choriomeningitis
virus infection of macrophages and subsequent induc-
tion of IFNab have also been shown to decrease IFNg
responsiveness and impair the control of histoplasmosis
infection (Villarete et al., 1995). It is therefore possible
that MCMV-induced IFNab production is responsible for
some of MCMV’s reported immunosuppressive activity.
The fact that IFNab plays a role in regulation of Mf
MHC class II expression in vivo and in vitro provides a
mechanism by which MCMV infection might alter im-
mune responsiveness. However, one might well expect
that other viruses, given the proper conditions of dose
and the immunocompetence of the host, could similarly
induce sufficient IFNab to dampen certain aspects of
IFNg activation of Mf. Thus it is possible that the mech-
anism that we have investigated here may be operative
during a number of viral infections, particularly in situa-
tions of severe infection.
We have demonstrated that IFNab induction by MCMV
is capable of inhibiting IFNg-mediated MHC class II
expression on Mf in vitro. Based on our results with
IFNabR2/2 mice this mechanism may have relevance
for Mf activation during MCMV infection in vivo. How-
ever, MCMV may also inhibit MHC class II expression via
IFNab-independent mechanisms. HCMV has been dem-
onstrated to impair IFNg-induced MHC class II expres-
FIG. 8. IFNab mediates the inhibition of MHC class II expression in MCMV-infected BMMf cultures. (A) BMMf from wildtype 129 or IFNabR2/2
mice were mock infected or infected with MCMV at an m.o.i. of 0.125. At 24 h after virus infection, cells were treated with recombinant murine IFNg
(100 U/ml). At 48 h after IFNg treatment, cells were harvested and analyzed for MHC class II expression by flow cytometry (IAb). (B) BMMf from
wildtype 129 or IFNabR2/2 mice were treated with murine IFNa and IFNb (250 U/ml each) or media alone for 48 h. Cells were then harvested and
analyzed for MHC class I (H-2Kb) expression by flow cytometry. Shown are representative histograms. Experiments were performed a total of three
times for MCMV-infected BMMf and twice for IFNab treatment.
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sion in infected endothelial cells (Scholz et al., 1992;
Sedmak et al., 1994). Though IFNb may play some role in
HCMV-mediated inhibition of endothelial cell MHC class
II expression, direct infection also appears to result in
inhibition of MHC class II expression (Scholz et al., 1992;
Sedmak et al., 1995, 1994). Long-term infection of Mf
with HCMV also results in decreased MHC class II
expression (Fish et al., 1996). Consistent with this, we
also observe IFNab-independent inhibition of MHC
class II expression in Mf directly infected with MCMV
(manuscript in preparation). Therefore, in addition to the
IFNab-mediated effects on MHC class II expression
reported here, MCMV infection may inhibit MHC class II
expression via other mechanisms.
METHODS
Abbreviations
The abbreviations used in this paper are as follows:
ATCC, American Type Culture Collection; BMMf, bone
marrow-derived Mf; DMEM, Dulbecco’s modified Ea-
gle’s medium; FCS, fetal calf serum; FITC, fluorescein
isothiocyanate; HCMV, human cytomegalovirus; HBSS,
Hanks’ balanced salt solution; HEPES, N-2-hydroxyeth-
ylpiperazine-N9-ethanesulfonic acid; HSV, herpes sim-
plex virus serotype 1; ICAM-1, intracellular adhesion mol-
ecule 1; IFN, interferon; IL, interleukin; ip, intraperitoneal;
IU, international units; LCMed, L-cell-conditioned media;
MAB, monoclonal antibody; MCMV, murine cytomegalo-
virus Smith strain (Smith, 1954); MEF, mouse embryo
fibroblasts; MHC, major histocompatibility complex; Mf,
monocyte/macrophage; NK, natural killer; PBS, phos-
phate-buffered saline; PECs, peritoneal exudate cells;
SCID, severe combined immunodeficient; TNF, tumor ne-
crosis factor; UV, ultraviolet.
Medium and Mf cell culture
All tissue culture media contained 2 mM L-glutamine,
100 U penicillin/ml, and 100 mg/ml streptomycin (Bioflu-
ids, Rockville, MD). 3T12 and Vero cells were maintained
as described (Heise and Virgin, 1995). Virus stocks were
grown and diluted in low endotoxin lots (, 0.025 ng/ml)
of DMEM containing 10% FCS (DMEM10%)(Heise and
Virgin, 1995). PECs were harvested as described previ-
ously (Heise and Virgin, 1995). BMMf were differenti-
ated for 7 days in low endotoxin DMEM supplemented
with 10% FCS, 5% horse serum (Sigma, St. Louis MO), 2
mM L-glutamine, 1 mM sodium pyruvate (Biofluids), and
20% LCMed. Differentiated Mf (7 days postharvest on-
ward) were maintained in media containing 10% LCMed.
LCMed consisted of DMEM10% from NCTC clone 929
cell (ATCC CCL 1) cultures maintained for 7 to 10 days.
Supernatant (LCMed) was removed from the cells, cen-
trifuged (1500 g for 10 min), filtered through 0.22-mm
filters (Nalge, Rochester NY), and stored at 220°C.
Viruses and viral assays
MCMV (ATCCNo. VR-194, Lot 10) and HSV strain KOS
(the gift of P. Olivo) were maintained as described (Heise
and Virgin, 1995). Briefly, MCMV was grown and titered in
BALB/3T12-3 fibroblasts (ATCC, CCL 164), while HSV was
grown and titered in Vero cells (ATCC, CCL 81). Control
cell extracts were prepared from mock-infected cells
FIG. 9. MCMV infection induced Mf MHC class II expression more
rapidly in mice lacking a functionally IFNab receptor. (A) Immunocom-
petent CB17 or 129 mice were infected ip with 106 PFU of MCMV. PECs
from three mice per group were harvested on days 3, 5, and 7 postin-
fection and pooled, and the percentage of MHC class II-positive (IEd,
CB17; IAb, 129) Mf was determined by flow cytometry and plotted over
time. Each line represents an independent experiment. (B) PECs from
IFNabR2/2 or 129 mice infected with 106 PFU of MCMV or mock
infected were harvested on day 3 postinfection. MHC class II (IAb)
expression on the Mf population was determined on day 3 postinfec-
tion. Shown is a representative histogram. (C) The percent MHC class
II-positive Mf was determined by flow cytometry for the Mf population
from B. Experiments were performed twice.
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treated identically to infected cultures. Inactivated virus
was prepared by UV irradiation as described (Heise and
Virgin, 1995), and no viable virus was detected by plaque
assay after UV irradiation. 3T12 and Vero cells as well as
MCMV stocks were negative for mycoplasma using the
Mycoplasma TC test kit (Gen-Probe, San Diego CA).
Mouse embryo fibroblasts (MEFs) were prepared from
day 15–18 Balb/c embryos as described previously (Pol-
lock and Virgin, 1995). Virus was quantitated by plaque
assay (Heise and Virgin, 1995).
Animals, animal infection, in vivo cytokine treatment,
and tissue harvest
Four- to 12-week-old Balb/c, CB17, and CB17 back-
ground SCID mice (H-2d) were housed in a Biosafety
Level 2 facility at Washington University in accordance
with all federal and university policies. Mice with a null
mutation in the IFNab receptor on the 129Ev/Sv back-
ground (IFNabR2/2)(Muller et al., 1994) were bred at
Washington University. Sentinel animals were assayed
every 3 months and were negative for adventitious
mouse pathogens by serology. Mice (n 5 2 or 3) were
infected ip with virus (or mock control) diluted in
DMEM10%. Mice were sacrificed 7 days after infection
except where noted, and PECs harvested by peritoneal
lavage using 10 ml/mouse HBSS1% (Heise and Virgin,
1995). For in vivo treatment with IFNg, SCID mice were
either mock infected or infected with 106 PFU of MCMV,
HSV strain KOS, or UV inactivated MCMV. On days 4–6
postinfection mice were injected ip with 3 mg/mouse
recombinant mouse IFNg (9.8 3 106 IU/mg)(the gift of
Genentech, San Francisco CA) in 200 ml pyrogen-free
normal saline (Baxter, Deerfield IL). Control mice re-
ceived pyrogen-free normal saline alone.
Measurement of serum IFN levels
Groups of CB17 SCID mice were inoculated ip with
either medium or MCMV (104 or 106 PFU). At various
times after infection mice were sacrificed and serum was
collected. IFN levels were assayed using inhibition of
vesicular stomatitis virus CPE on L929 fibroblast mono-
layers essentially as described (Cousens et al., 1997;
Grundy et al., 1982; Orange and Biron, 1996). Briefly,
serial dilutions of serum were added to monolayers of
L929 cells (3.6 3 104/well) for 24 h prior to addition of a
dilution of VSV that gave total CPE in control wells within
24–48 h. Wells were stained with crystal violet in meth-
anol and then read by two independent observers in
comparison to a standard curve generated using a mix-
ture of IFNa and IFNb (Lee Biomolecular). To assure that
IFN measured was IFNab and not IFNg, control experi-
ments in which a neutralizing anti-IFNg antibody [H22
(Schreiber et al., 1985)] was added to serum samples
containing IFN activity were performed. Addition of H22
at a concentration of 50 mg/ml final concentration neu-
tralized . 3000 units/ml of recombinant IFNg but did not
alter protection of L929 monolayers by serum from in-
fected mice.
Analysis of PECs and Mf cell surface protein
expression
Flow cytometry was performed as previously published
(Heise and Virgin, 1995). In brief, 106 PECs/sample were
incubated in primary antibodies (Heise and Virgin, 1995) for
30 min on ice. Cells were washed and incubated with
secondary antibody for 30 min on ice, washed, and stored
in 1% paraformaldehyde in PBS at 4°C. Flow cytometry was
done on a FACScan (Becton–Dickenson, San Jose CA) and
data were analyzed using Consort 30 or CellQuest software
(Becton–Dickenson) or on an Epics flow cytometer (Coulter,
Miami FL) using XL analysis software (Coulter) or WinMDI
2.0 (Joseph Trotter, San Diego CA). Single color histograms
for Mf MHC class II expression were generated using
F4/80 expression and forward scatter to gate on Mf (Heise
and Virgin, 1995). The percentage of Mf expressing MHC
class II above background was determined by setting
markers on unstained Mf from mock-infected mice to ex-
clude negative cells. These markers were applied to exper-
imental groups, and the percentage of cells above back-
ground staining was calculated. Fluorescent microscopy
was performed as previously described (Bancroft et al.,
1986). Differential counts were performed in a blinded man-
ner on PECs adhered to glass slides and stained with
Wright’s stain (Heise and Virgin, 1995). Cell yield per mouse
for each cell type was calculated by multiplying the total cell
yield per mouse by the percentage of each cell type. The
number of MHC class II-positive Mf per mouse was de-
termined by multiplying the total number of Mf/mouse by
the percentage of MHC class II-positive Mf as determined
by flow cytometry.
Mf culture and in vitro MHC class II expression
assays
Peritoneal Mf were elicited by ip injection with thiogly-
collate broth (Becton–Dickinson, Cockeysville MD). Briefly,
2 ml of thioglycollate was administered ip to 4- to 6-week-
old female Balb/c mice and PECs were harvested 4 days
later. Thioglycollate-elicited PECs were plated at 4 3 106
cells/dish in 15 3 100 mm tissue culture dishes (Sarstedt,
Newton NC) in RPMI10%, for 48 h before infection. Bone
marrow was harvested by lavage through the femur and
tibia of 4- to 8-week-old Balb, 129, or IFNabR2/2 mice.
Bone marrow cells (5 3 106) were plated in 15 3 100 mm
non-tissue-culture-treated dishes (Sarstedt) for 7 days in
medium containing 20% LCMed. After 7 days in culture, Mf
were gently scraped and replated at 2.5 3 106 cells/dish in
medium containing 10% LCMed. This method has been
shown to generate cultures that are 98% Mf (Fischer et al.,
1988), and in our hands Mf cultures are at least 95% F4/80
positive (data not shown). Mf cultures were mock infected
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or infected with MCMV, or UV-inactivated MCMV, at an
m.o.i. of 0.1 or 0.2 (BMMf) or 0.25 (PECs) for 1 h at 37°C in
5% CO2 with rocking every 15 min. Following infection, cells
were incubated for 24 h at 37°C in 5% CO2. Mf cultures
were then treated with or without 100 or 500 IU/ml recom-
binant mouse IFNg (Genentech) for 48 h. Mf viability was
determined by trypan blue exclusion, and no differences
were observed between mock-infected and MCMV-in-
fected groups. Cells were then harvested by gentle scrap-
ing, fixed, and analyzed for MHC class II and MHC class I
expression by flow cytometry (see above). The responsive-
ness of IFNabR2/2 BMMf to IFNab was addressed by
treating wildtype 129 or IFNabR2/2 BMMf with a combi-
nation of 250 U/ml murine IFNa (Lee Biomolecular Re-
search, San Diego CA) and 250 U/ml murine IFNb (Lee
Biomolecular Research) for 48 h. Induction of MHC class I
expression was then evaluated by flow cytometry (Heise
and Virgin, 1995).
Cytokine neutralization in vitro
BMMf cultures were generated and infected with
MCMV as described above. Polyclonal antibody against
IFNab (Gresser et al., 1976)(kindly provided by Dr. Ion
Gresser) was added at a 1/200 dilution, which has pre-
viously been shown to be effective at neutralizing IFNab
bioactivity (Chong et al., 1983). Following initial infection
and antibody addition, cells were incubated for 24 h at
37°C in 5% CO2. Cultures were then treated with 100
IU/ml of recombinant mouse IFNg (Genentech) for 48 h
and then harvested and assayed for cell surface protein
expression as above.
Limiting dilution analysis of MCMV-infected PECs
PECs from SCID mice infected with 104 or 106 PFU of
MCMV were harvested 7 days after infection, washed to
remove unbound virus, and cultured with MEF cells un-
der conditions previously shown to detect 1 PFU of
MCMV (Pollock and Virgin, 1995). Briefly, serial 1:1 dilu-
tions starting with 104 PECs/well down to 78 PECs/well
(24–36 wells/dilution) were plated in 96-well clusters
(Costar, Cambridge MA) containing 5 3 103 MEFs. Pro-
ductive infection was scored by the presence of typical
MCMV CPE on day 7 or 14. After 2 weeks, supernatant
was removed and incubated with a new MEF monolayer
to detect low levels of virus (three experiments). Alterna-
tively, limiting dilution cultures were scored every 7 days
for 4 weeks (two experiments). The number of positive
wells at each dilution was then used to determine the
frequency of productively infected cells by the minimum
x method (Taswell, 1981).
Limiting dilution PCR for MCMV genome-bearing cells
To determine the frequency of peritoneal cells carrying
the MCMV genome, a previously published PCR method
(Eron et al., 1992) was adapted to analyze limiting dilu-
tions of PECs. PECs were harvested on day 7 postinfec-
tion from SCID mice infected with 106 PFU of MCMV.
Cells were washed three times in PBS to remove free
virus and maintained in PBS at 4°C until immediately
before lysis. Cells were pelleted by centrifugation (16,000
g for 4 s) and briefly resuspended in water. Cells were
then aliquotted at 103, 102, or 10 cells per reaction tube in
5 ml of water, followed by the addition of 5 ml of lysis
buffer [100 mM KCl, 20 mM Tris–HCl (pH 8.3), 5 mM
MgCl2, 1% Nonidet P-40 (Sigma), 1% Tween 20 (Sigma),
and O.02% proteinase K (Boehringer Mannheim, India-
napolis IN)]. Cells were lysed for 12 h at 56°C followed by
a 15-min 95°C incubation to inactivate the proteinase K.
PCR cocktail was added directly to each tube containing
cell lysate with adjustments in KCl, Tris–HCl, and MgCl2
concentrations to assure that PCR reaction conditions
were identical to those previously described (Pollock and
Virgin, 1995). Nested PCR using primers for the MCMV
ie1 gene was performed (Pollock and Virgin, 1995) on
each sample using a Perkin–Elmer GeneAmp PCR sys-
tem 9600. Reaction products were visualized by ethidium
bromide staining of agarose gels. Every PCR reaction
contained negative controls consisting of either lysis
buffer or water alone. Positive controls and sensitivity
determination were performed in each PCR experiment
and included tubes containing either lysis buffer alone or
lysate from mock-infected PECs to which 1, 5, or 10
copies of the MCMV ie1 containing plasmid pAMB25
(Keil et al., 1984) was added. Previous data demonstrated
that the MCMV genome can be quantitatively recovered
during DNA extraction from tissue (Pollock and Virgin,
1995). In addition, when plasmid was added prior to
digestion of cells, sensitivity was not significantly altered
(not shown).
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